Benzisothiazol-3(1H)-one-5-sulfonyl derivatives as chemokine receptor modulators
AssigneeAllergan, Inc.
InventorsHaiqing Yuan, Richard L. Beard, Xiaoxia Liu, John E. Donello, Veena Viswanath
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel benzisothiazol-3(1H)-one-5-sulfonyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of chemokine receptors.
Claims14
A compound represented by Formula I, its enantiomers, diastereoisomers or a pharmaceutically acceptable salt thereof,
- wherein:
- R1 is substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-10 cycloalkyl, substituted or unsubstituted C3-10 cycloalkenyl or substituted or unsubstituted C6-10 aryl;
- R2 is substituted or unsubstituted C1-6 alkyl;
- R3 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OC1-3 alkyl, CN, NO2, C2-6 alkenyl, C2-6 alkynyl, C(O)R6, NR7R8 or hydroxyl;
- R4 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OC1-3 alkyl, CN, NO2, C2-6 alkenyl, C2-6 alkynyl, C(O)R6, NR7R8 or hydroxyl;
- R5 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OC1-3 alkyl, CN, NO2, C2-6 alkenyl, C2-6 alkynyl, C(O)R6, NR7R8 or hydroxyl;
- X is O, S or NH;
- R6 is H or substituted or unsubstituted C1-6 alkyl;
- R7 is H or substituted or unsubstituted C1-6 alkyl;
- R8 is H or substituted or unsubstituted C1-6 alkyl;
- with the proviso that the compound of Formula I does not have one of the following structures:
A method of treating a disorder associated with chemokine receptor inhibition, which comprises administering to a mammal in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I
- wherein:
- R1 is substituted or unsubstituted C1-10 alkyl, substituted or unsubstituted heterocycle, substituted or unsubstituted C3-10 cycloalkyl, substituted or unsubstituted C3-10 cycloalkenyl or substituted or unsubstituted C6-10 aryl;
- R2 is substituted or unsubstituted C1-6 alkyl;
- R3 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OC1-3 alkyl, CN, NO2, C2-6 alkenyl, C2-6 alkynyl, C(O)R6, NR7R8 or hydroxyl;
- R4 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OC1-3 alkyl, CN, NO2, C2-6 alkenyl, C2-6 alkynyl, C(O)R6, NR7R8 or hydroxyl;
- R5 is H, substituted or unsubstituted C1-6 alkyl, halogen, substituted or unsubstituted —OC1-3 alkyl, CN, NO2, C2-6 alkenyl, C2-6 alkynyl, C(O)R6, NR7R8 or hydroxyl;
- X is O, S or NH;
- R6 is H or substituted or unsubstituted C1-6 alkyl;
- R7 is H or substituted or unsubstituted C1-6 alkyl;
- R8 is H or substituted or unsubstituted C1-6 alkyl;
- with the proviso that the compound of Formula I does not have one of the following structures:
Dependencies are inferred from the claim text.